期刊文献+

超声造影、CT和MRI对大肠癌肝转移的评估价值比较 被引量:4

Comparison of Evaluation Value of Contrast- Enhanced Ultrasound,CT and MRI on Colorectal Liver Metastases
下载PDF
导出
摘要 目的探讨超声造影、CT和MRI对大肠癌肝转移的评估价值的差异。方法采用超声造影、CT和MRI对2013年1月至2014年1月期间我院收治的疑伴肝转移的大肠癌患者88例进行肝转移情况检查。以实验室检查结合肿瘤声学造影等结果为金标准,分析超声造影、CT和MRI诊断大肠癌肝转移的准确性。统计超声造影、CT和MRI显示大肠癌肝转移灶的数目、大小及大肠癌肝转移超声造影特点。结果超声造影、CT和MRI诊断大肠癌肝转移的敏感度、特异度、准确性、Kappa值等比较差异无统计学意义(P〉0.05)。CT和MRI显示总病灶数和病灶大小比较差异无统计学意义(P〉0.05)。CT显示最小病灶体积大于超声造影和MRI,超声造影显示的总病灶数及0~1 cm和1~3 cm转移灶数较CT和MRI增加,超声造影可更好的显示较小转移灶,差异有统计学意义(P〈0.05)。79例肝转移138个重点观察转移病灶超声灌注呈环状增强、团状增强、延迟增强和无增强4个特征,各特征患者比例分别为77.22%、13.92%、2.53%和6.33%,其中团状增强开始增强时间和消退时间最短,其次为环状增强,延迟增强开始增强时间和消退时间均较长,差异有统计学意义(P〈0.05)。结论超声造影、CT和MRI诊断大肠癌肝转移准确性均较高,其中超声造影更有利于肝转移灶数目、部位、大小等的确认,可有效显示微小转移灶,为大肠癌临床分期和治疗提供有力依据,值得临床推广使用。 Objective To investigate the evaluation value of Contrast- enhanced ultrasound,CT and MRI on colorectal liver metastases. Methods Contrast- enhanced ultrasound,CT and MRI were used to evaluate the liver metastasis of 88 patients with colorectal cancer in our hospital from January,2013 to January,2014. Laboratory tests combined with acoustic imaging results were taken as the gold standard,and the evaluation value of Contrast- enhanced ultrasound,CT and MRI on colorectal liver metastases were compared. The number and size of colorectal liver metastases measured by contrast- enhanced ultrasound,CT and MRI and the ultrasonic imaging features of colorectal liver metastases were statistically analyzed. Results accuracy,sensitivity,specific degrees and Kappa value of contrast- enhanced ultrasound,CT and MRI in the diagnosis of colorectal liver metastases had no statistical significant differences( P〉0. 05). Total number of liver metastases measured by CT and MRI showed no statistical significant differences( P〉0. 05). CT demonstrating the focal area of minimum volume was greater than that of the ultrasonic imaging and magnetic resonance imaging( MRI); the total number of liver metastases and liver metastases in 0 to 1 cm and 1 to 3 cm size measured by ultrasound imaging metastases were higher than that of the CT and MRI,contrast- enhanced ultrasound can better show small metastases of colorectal cancer; and the difference was statistically significant( P〈0. 05). patients rate of patients showed 138 key observation metastatic lesions in 79 cases of colorectal cancer patients with liver metastasis showed ultrasound perfusion characteristics as rimlike enhancement,regimental enhancement,delayed enhancement and no enhanced images were 77. 22%,13. 92%,2. 53% and 6. 33%;rimlike enhancement had shortest time to begin to enhance strengthen and fade,regimental enhancement followed by rimlike enhancement,delayed enhancement start had longer time to begin to enhance strengthen and fade; and the difference was statistically significant( P〈0. 05). Conclusion Evaluation value of contrast- enhanced ultrasound,CT and MRI in the diagnosis of colorectal liver metastases accuracy was high. The ultrasonic imaging can better show liver metastases number,location,size,etc,and small liver metastases so as to provide powerful basis for clinical staging and treatment of colorectal cancer.
作者 郑泽锋
出处 《哈尔滨医药》 2015年第5期348-351,共4页 Harbin Medical Journal
关键词 超声造影 CT MRI 大肠癌 肝转移 Contrast-enhanced ultrasound Computed tomography(CT) Magnetic resonance imaging(MRI) Colorectal cancer Liver metastases
  • 相关文献

参考文献5

二级参考文献28

  • 1Judith YMN Engwegen,Helgi H Helgason,Annemieke Cats,Nathan Harris,Johannes MG Bonfrer,Jan HM Schellens,Jos H Beijnen.Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry[J].World Journal of Gastroenterology,2006,12(10):1536-1544. 被引量:45
  • 2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Ciin, 2005, 55(2):74-108.
  • 3Costa FF, Verbisck NV, Salim AC, et al. Epigenetic silencing of the adhesion molecule ADAm23 is highly frequent in breast tumors[J]. Oncogene, 2004, 23(7): 1481-1488.
  • 4Takada H, lmoto I, Tsuda H, et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylatio[J]. Oncogene, 2005, 24(54):805 1-8060.
  • 5Hagihara A, Miyamolo K, Furuta J, et al. Identification of 27 5' CpG islands aberrantly melhylated and 13 genes silenced in human pancreatic cancers[J]. Oncogene, 2004, 23(53):8705-8710.
  • 6Calmon MF, Colombo J, Carvalho F, et al. Methylation profile of genes CDKN2A(PI4 and PI 6), DAPKI, CDHI, and ADAM23 inhead and neck cancer[J]. Cancer Genet Cylogenet, 2007, 1 73(I): 31-37.
  • 7Choi JS, Kim KH, Jeon YK, et al. Promoter hyperrnethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues[J]. Int J Cancer, 2009, 124(6): 1258-1262.
  • 8Cal S, Freije JM, L 6 pez JM, et al. ADAM 23/MDC3, a human disintegrin that promotes cel[ adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism[J]. Mol Biol Cell, 2000, I 1(4):1457-1469.
  • 9Kindler HL, Shulman KL. Metastatic colorectal cancancer[J]. Curr Treat Options Oncol. 2001,2(6): 459-471.
  • 10Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity[J]. Trends Genet, 2000, 16(2): 83-87.

共引文献16

同被引文献27

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部